NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Adkins, Chris E ^a,b   Nounou, Mohamed I ^b,c   Hye, Tanvirul ^b   Mohammad, Afroz S ^a,b   Terrell Hall, Tori ^a,b   Mohan, Neel K ^d   Eldon, Michael A ^d   Hoch, Ute ^d   Lockman, Paul R ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Alexandria University Faculty of Pharmacy   (Egypt)

^d NEKTAR THERAPEUTICS   (United States)

Author keywords

Brain metastasis; Breast cancer; NKTR 102; PEGylated irinotecan

Indexed keywords

ETIRINOTECAN PEGOL; FIRTECAN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TUMOR BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG PENETRATION; DRUG RELEASE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERMEABILITY BARRIER; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG MONITORING; DRUG SCREENING; LUMINESCENCE; METABOLISM; MORTALITY; PATHOLOGY; PERMEABILITY; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG MONITORING; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MOLECULAR STRUCTURE; PERMEABILITY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944050899     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1672-4     Document Type: Article

References (61)

1. German RR, Fink AK, Heron M, Stewart SL, Johnson CJ, Finch JL, et al. The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol. 2011;35(2):126-31.
2. Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin. 1999;49(3):138-44.
3. Guerin S, Laplanche A. [Statistics of mortality in 1994 and predictions of death caused by cancer 1997]. Presse Med. 1997;26(24):1149-53.
4. Mera SL. Cancer mortality statistics in England and Wales. Med Lab Sci. 1992;49(3):232.
5. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309(8):800-5.
6. Soffietti R, Ruda R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol. 2008;20(6):676-84.
7. Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clin Dermatol. 2013;31(3):264-81.
8. Tomasello F, La Torre D. Brain metastases: Can we do more? World Neurosurg. 2014;81(1):52-53.
9. Lin NU. Brain metastases in HER2-positive breast cancer. Lancet Oncol. 2013;14(3):185-6.
10. Lechapt-Zalcman E, Karanian-Philippe M, Rousseau A. [Diagnosis of brain metastases: an update in 2012]. Bull Cancer. 2013;100(1):29-34.
11. Hofer S, Pestalozzi BC. Treatment of breast cancer brain metastases. Eur J Pharmacol. 2013.
12. Niwinska A, Olszewski W, Murawska M, Pogoda K. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. J Neurooncol. 2011;105(3):547-53.
13. Caffo M, Barresi V, Caruso G, Cutugno M, La Fata G, Venza M, et al. Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci. 2013;14(1):2135-74.
14. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5):352-63.
15. Smith QR. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm Biotechnol. 1996;8:285-307.
16. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54-61.
17. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin cancer res : an official journal of the American Association for Cancer Research. 2010;16(23):5664-78.
18. Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155(2):185-97.
19. Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, et al. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011;13(12):1288-95.
20. Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, et al. Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. J controlled release : official journal of the Controlled Release Society. 2012;158(1):34-43.
21. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, et al. Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer. Pharm Res. 2009.
22. Birngruber T, Raml R, Gladdines W, Gatschelhofer C, Gander E, Ghosh A, et al. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,((R))/Doxil((R))--a cerebral open flow microperfusion pilot study. J Pharm Sci. 2014;103(7):1945-8.
23. Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014;9(1), e82331.
24. Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, et al. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine. 2014.
25. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann oncol : official journal of the European Society for Medical Oncology / ESMO. 1995;6(2):141-51.
26. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905-14.
27. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-7.
28. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11F205, F220, F221 and V222 study groups. Br J Cancer. 2000;83(4):431-7.
29. Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann oncol : official journal of the European Society for Medical Oncology / ESMO. 2003;14(4):603-14.
30. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J clin oncol : official journal of the American Society of Clinical Oncology. 1999;17(5):1516-25.
31. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8(2):189-93.
32. Horowitz RW, Wadler S, Wiernik PH. A review of the clinical experience with irinotecan (CPT-11). Am J Ther. 1997;4(5-6):203-10.
33. Chabot GG. Clinical pharmacology and pharmacodynamics of irinotecan. A review. Ann N Y Acad Sci. 1996;803:164-72.
34. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs. 1996;52(4):606-23.
35. Bonneterre J. Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan. Bull Cancer. 1995;82(8):623-8.
36. Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014.
37. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin cancer res : an official journal of the American Association for Cancer Research. 2013;19(1):268-78.
38. Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J clin oncol : official journal of the American Society of Clinical Oncology. 2013;31(32):4060-6.
39. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013;14(12):1216-25.
40. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs. 1996;7(1):78-86.
41. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin cancer res : an official journal of the American Association for Cancer Research. 2003;9(7):2849-55.
42. On NH, Mitchell R, Savant SD, Bachmeier CJ, Hatch GM, Miller DW. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J Neurooncol. 2012.
43. Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, et al. A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier. Cancer prev res. 2015;8(1):68-76.
44. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997;33(4):245-59.
45. Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol Cancer Ther. 2013;12(11):2389-99.
46. Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin cancer res : an official journal of the American Association for Cancer Research. 2013;19(23):6404-18.
47. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25-37.
48. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752-6.
49. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71-9.
50. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387-92.
51. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-64.
52. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491-9.
53. Liu J, Yu M, Zhou C, Yang S, Ning X, Zheng J. Passive Tumor Targeting of Renal-Clearable Luminescent Gold Nanoparticles: Long Tumor Retention and Fast Normal Tissue Clearance. J Am Chem Soc. 2013.
54. Nakagawa H, Groothuis DR, Owens ES, Fenstermacher JD, Patlak CS, Blasberg RG. Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain. J cereb blood flow metab : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1987;7(6):687-701.
55. Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, et al. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. Front pharmacol. 2013;4:136.
56. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur j pharm sci : official journal of the European Federation for Pharmaceutical Sciences. 2009;36(4-5):580-90.
57. Robert J, Rivory L. Pharmacology of irinotecan. Drugs of today. 1998;34(9):777-803.
58. Zabaleta V, Ponchel G, Salman H, Agueros M, Vauthier C, Irache JM. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm. 2012;81(3):514-23.
59. Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci. 2002;91(9):1980-90.
60. Sane R, Agarwal S, Elmquist WF. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug metab dispos: the biological fate of chemicals. 2012;40(8):1612-9.
61. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, et al. Why Clinical Modulation of Efflux Transport at the Human Blood-brain Barrier Is Unlikely: The ITC Evidence-Based Position. Clin Pharmacol Ther. 2013.